<DOC>
<DOCNO>EP-0636626</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Pyrazolopyrimidine Derivatives.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31505	A61K31505	A61P900	A61P900	A61P910	A61P912	A61P1100	A61P1100	A61P4300	A61P4300	C07D48700	C07D48704	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P9	A61P9	A61P11	A61P11	A61P43	A61P43	C07D487	C07D487	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Pyrazolo[3,4-d]pyrimidin-4-one derivatives of formula (I) 


and salts and solvates thereof are described, in which:
 

R¹ represents arylmethyl or C₁₋₆alkyl optionally substituted by one or more 
fluorine atoms;

 
R² represents methyl;

 
R³ represents C₂₋₄alkyl;

 
R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, 

(CH₂)
m
NR¹⁰C(=Y)R¹¹ or a 5-membered heterocyclic ring selected from 
thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a C₁₋ 

₄alkyl or aryl group; or when R¹ is arylmethyl or C₁₋₆alkyl substituted by one or 
more fluorine atoms then R⁴ may also represent hydrogen;

 
R⁵ represents hydrogen or C₁₋₆alkyl;

 
R⁶ represents hydrogen or C₁₋₆alkyl;

 
R⁷ represents hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋₄alkyl;

 
R⁸ represents hydrogen or C₁₋₆alkyl;

 
R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² or 

C(=NCN)NR¹³R¹⁴;
 

R¹⁰ represents hydrogen or C₁₋₆alkyl;
 

R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen atoms, 
or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, CH₂NR¹⁷R¹⁸ or R¹⁰ 

and R¹¹ together represent -A(CH₂)
n
-;
 

 
R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl;

 
R¹³ represents hydrogen or C₁₋₆alkyl;

 
R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ 

together with the nitrogen atom to which they are attached form a morpholine, 

piperazine or N-C₁₋₄alkylpiperazine ring;
 

R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together represent 
-A(CH₂)
n
-;
 

R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, CO₂R¹², CH₂CO₂R¹² 
or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form 

a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring;
 

R¹⁷ represents hydrogen or C₁₋₆alkyl;
 

R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ and 
R¹⁸ together with the nitrogen atom to which they are attached form a 

morpholine, piperazine or N-C₁₋₄alkylpiperazine ring;
 

A represents CH₂ or C=O;
 

m represents zero or 1;
 

n represents 1,2 or 3;
 

X represents S or NH, or when R⁷ represents amino then X may also represent 
O;

 
Y represents O or S; for use in therapy. 
These compounds are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate 
specific phosphodiesterase (cGMP specific PDE) and are 

useful in a variety of therapeutic areas, including the treatment of cardiovascular 
disorders. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
GLAXO LAB SA
</APPLICANT-NAME>
<APPLICANT-NAME>
LABORATOIRES GLAXO SA
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DODIC NERINA LABORATOIRES GLAX
</INVENTOR-NAME>
<INVENTOR-NAME>
DUMAITRE BERNARD ANDRE LABORAT
</INVENTOR-NAME>
<INVENTOR-NAME>
DODIC, NERINA, LABORATOIRES GLAXO SA
</INVENTOR-NAME>
<INVENTOR-NAME>
DUMAITRE, BERNARD ANDRE, LABORATOIRES GLAXO SA
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to a series of pyrazolo[3,4-d]pyrimidin-4-one derivatives, 
to processes for their preparation, pharmaceutical compositions containing them, 
and their use as therapeutic agents. In particular, the invention relates to 
pyrazolo[3,4-d]pyrimidin-4-one derivatives which are potent and selective 
inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase 
(cGMP specific PDE) having utility in a variety of therapeutic areas where such 
inhibition is thought to be beneficial, including the treatment of cardiovascular 
disorders. Thus, according to a first aspect, the present invention provides compounds of 
formula (I) 
and salts and solvates (e.g. hydrates) thereof, in which:
 
R¹ represents arylmethyl or C₁₋₆alkyl optionally substituted by one or more 
fluorine atoms;
 
R² represents methyl;
 
R³ represents C₂₋₄alkyl;
 
R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, 
(CH₂)mNR¹⁰C(=Y)R¹¹ or a 5-membered heterocyclic ring selected from thienyl, 
thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a C₁₋₄alkyl or aryl 
group; or when R¹ is arylmethyl or C₁₋₆alkyl substituted by one or more fluorine 
atoms then R⁴ may also represent hydrogen;
 
R⁵ represents hydrogen or C₁₋₆alkyl;
 
R⁶ represents hydrogen or C₁₋₆alkyl;
 
 
R⁷ represents hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋₄alkyl;
 
R⁸ represents hydrogen or C₁₋₆alkyl;
 
R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² or 
C(=NCN)NR¹³R¹⁴;
 
R¹⁰ represents hydrogen or C₁₋₆alkyl;
 
R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen atoms, 
or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, CH₂NR¹⁷R¹⁸ or R¹⁰ 
and R¹¹ together represent -A(CH₂)n-;
 
R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl;
 
R¹³ represents hydrogen or C₁₋₆alkyl;
 
R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ 
together with the nitrogen atom to which they are attached form a morpholine, 
piperazine or N-C₁₋₄alkylpiperazine ring;
 
R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together represent 
-A(CH₂)n-;
 
R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, CO₂R¹², CH₂CO₂R¹² 
or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form 
a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring;
 
R¹⁷ represents hydrogen or C₁₋₆alkyl;
 
R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ and 
R¹⁸ together with the nitrogen atom to which they are attached form a 
morpholine, piperazine or
</DESCRIPTION>
<CLAIMS>
Compounds of formula (I) 
 

and salts and solvates (e.g. hydrates) thereof, in which: 
R¹ represents arylmethyl or C₁₋₆alkyl optionally substituted by one or 

more fluorine atoms; 
R² represents methyl; 

R³ represents C₂₋₄alkyl; 
R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, 

(CH₂)mNR¹⁰C(=Y)R¹¹ or a 5-membered heterocyclic ring selected from 
thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a 

C₁₋₄alkyl or aryl group; or when R¹ is arylmethyl or C₁₋₆alkyl substituted 
by one or more fluorine atoms then R⁴ may also represent hydrogen; 

R⁵ represents hydrogen or C₁₋₆alkyl; 
R⁶ represents hydrogen or C₁₋₆alkyl; 

R⁷ represents hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋ 
₄alkyl; 

R⁸ represents hydrogen or C₁₋₆alkyl; 
R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² 

or C(=NCN)NR¹³R¹⁴; 
R¹⁰ represents hydrogen or C₁₋₆alkyl; 

R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen 
atoms, or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, 

CH₂NR¹⁷R¹⁸ or R¹⁰ and R¹¹ together represent -A(CH₂)n-; 
R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl; 

R¹³ represents hydrogen or C₁₋₆alkyl;
 

R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ 
together with the nitrogen atom to which they are attached form a 

morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 
R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together 

represent -A(CH₂)n-; 
R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC
₁₋₄alkyl, CO₂R¹², 
CH₂CO₂R¹² or R¹⁵ and R¹⁶ together with the nitrogen atom to which 

they are attached form a morpholine, piperazine or N-C₁₋ 
₄alkylpiperazine ring; 

R¹⁷ represents hydrogen or C₁₋₆alkyl; 
R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ 

and R¹⁸ together with the nitrogen atom to which they are attached form 
a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 

A represents CH₂ or C=O; 
m represents zero or 1; 

n represents 1,2 or 3; 
X represents S or NH, or when R⁷ represents amino then X may also 

represent O; 
Y represents O or S; for use in therapy. 
Compounds of formula (I) 
 

and salts and solvates (e.g. hydrates) thereof, in which: 
R¹ represents arylmethyl or C₁₋₆alkyl optionally substituted by one or 

more fluorine atoms; 
R² represents methyl; 

R³ represents C₂₋₄alkyl;
 

R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, 
(CH₂)mNR¹⁰C(=Y)R¹¹ or a 5-membered heterocyclic ring selected from 

thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a 
C₁₋₄alkyl or aryl group; or when R¹ is arylmethyl or C₁₋₆alkyl substituted 

by one or more fluorine atoms then R⁴ may also represent hydrogen; 
R⁵ represents hydrogen or C₁₋₆alkyl; 

R⁶ represents hydrogen or C₁₋₆alkyl; 
R⁷ represents hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋ 

₄alkyl; 
R⁸ represents hydrogen or C₁₋₆alkyl; 

R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² 
or C(=NCN)NR¹³R¹⁴; 

R¹⁰ represents hydrogen or C₁₋₆alkyl; 
R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen 

atoms, or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, 
CH₂NR¹⁷R¹⁸ or R¹⁰ and R¹¹ together represent -A(CH₂)n-; 

R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl; 
R¹³ represents hydrogen or C₁₋₆alkyl; 

R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ 
together with the nitrogen atom to which they are attached form a 

morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 
R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together 

represent -A(CH₂)n-; 
R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, CO₂R¹², 

CH₂CO₂R¹² or R¹⁵ and R¹⁶ together with the nitrogen atom to which 
they are attached form a morpholine, piperazine or N-C₁₋ 

₄alkylpiperazine ring; 
R¹⁷ represents hydrogen or C₁₋₆alkyl; 

R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ 
and R¹⁸ together with the nitrogen atom to which they are attached form 

a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 
A represents CH₂ or C=O; 

m represents zero or 1; 
n represents 1,2 or 3;

 
X represents S or NH, or when R⁷ represents amino then X may also 

represent O; 
Y represents O or S; with the proviso that when R¹ represents C₁₋₆alkyl 

and R⁵ represents hydrogen then R⁴ cannot represent nitro or NH₂. 
A compound according to Claim 1 or Claim 2 in which R¹ represents a 
C₁₋₃alkyl group. 
A compound according to any preceding claim in which R³ represents a 
C₂₋₃alkyl group. 
A compound according to any preceding claim in which R⁴ is a group 
linked to the benzene ring of the rest of the molecule via a nitrogen atom. 
A compound according to Claim 5 in which R⁴ represents NHCOR¹¹ 
(where R¹¹ is methyl, p-fluorophenyl, 2-thienyl or trifluoromethyl), NH₂, 

NHSO₂CH₃, NHCO₂CH₃, NHCO₂Et, NHCONHEt or NHCSNHEt. 
A compound according to any one of Claims 1 to 4 in which R⁴ is a 
thienyl, thiazolyl or 1,2,4-triazolyl ring each substituted by methyl or aryl. 
Compounds of formula (Ia) 
 

and physiologically acceptable salts and solvates (e.g. hydrates) thereof, 
in which R¹ represents C₁₋₃alkyl and R⁴ represents NHCOR¹¹ (where 

R¹¹ is methyl, p-fluorophenyl, 2-thienyl or trifluoromethyl, NHSO₂CH₃, 
 

NHCO₂CH₃, NHCO₂Et, NHCONHEt, NHCSNHEt or a thienyl, thiazolyl 
or 1,2,4-triazolyl ring each substituted by methyl or aryl. 
1,3-Dimethyl-6-(2-propoxy-5-acetamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one; 

1-ethyl-3-methyl-6-[2-propoxy-5-(4-methyl-2-thiazolyl)phenyl]-1,5-dihydropyrazolo[3,4-d]
pyrimidin-4-one; 
1-ethyl-3-methyl-6-[2-propoxy-5-(2-methyl-4-thiazolyl)phenyl]
-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one; 

1-ethyl-3-methyl-6-[2-propoxy-5-(2-(3-pyridyl)-4-thiazolyl)phenyl]-1,5-dihydropyrazolo[3,4-d]
pyrimidin-4-one; 
1,3-dimethyl-6-[2-propoxy-5-(2-methyl-4-thiazolyl)phenyl]
-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one; 

1,3-dimethyl-6-[2-propoxy-5-(3-phenyl-1,2,4-triazol-5-yl)phenyl]-1,5-dihydropyrazolo[3,4-d]
pyrimidin-4-one; 
1,3-dimethyl-6-(2-propoxy-5-methanesulfonamidophenyl)-1,5-dihydro-pyrazolo[3,4-d]
pyrimidin-4-one; 
and physiologically acceptable salts and 

solvates (e.g. hydrates) thereof. 
Compounds of formula (I) and salts and solvates (e.g. hydrates) thereof 
in which: 

R¹ represents C₁₋₆alkyl, 2,2,2-trifluoroethyl or benzyl; 
R² represents methyl; 

R³ represents C₂₋₄alkyl; 
R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, 

(CH₂)mNR¹⁰C(=Y)R¹¹ or thiazolyl or 1,2,4-triazolyl each ring optionally 
substituted by a C₁₋₄alkyl or aryl group; 

R⁵ represents hydrogen or C₁₋₆alkyl; 
R⁶ represents hydrogen or C₁₋₆alkyl; 

R⁷ represents, hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋ 
₄alkyl; 

R⁸ represents hydrogen or C₁₋₆alkyl; 
R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² 

or C(=NCN)NR¹³R¹⁴;
 

R¹⁰ represents hydrogen or C₁₋₆alkyl; 
R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen 

atoms, or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, 
CH₂NR¹⁷R¹⁸ or R¹⁰ and R¹¹ together represent -A(CH₂)n-; 

R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl; 
R¹³ represents hydrogen or C₁₋₆alkyl; 

R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ 
together with the nitrogen atom to which they are attached form a 

morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 
R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together 

represent -A(CH₂)n-; 
R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, CO₂R¹², 

CH₂CO₂R¹² or R¹⁵ and R¹⁶ together with the nitrogen atom to which 
they are attached form a morpholine, piperazine or N-C₁₋ 

₄alkylpiperazine ring; 
R¹⁷ represents hydrogen or C₁₋₆alkyl; 

R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ 
and R¹⁸ together with the nitrogen atom to which they are attached form 

a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; 
A represents CH₂ or C=O; 

m represents zero or 1; 
n represents 1,2 or 3; 

X represents S or NH, or when R⁷ represents amino then X may also 
represent O; 

Y represents O or S, with the proviso that when R¹ represents C₁₋₆alkyl 
and R⁵ represents hydrogen then R⁴ cannot represent nitro or NH₂. 
A pharmaceutical composition comprising a compound of formula (I) or a 
physiologically acceptable salt or solvate thereof (as defined in Claim 1) 

together with a pharmaceutically acceptable diluent or carrier. 
A process for the preparation of a compound of formula (I) or a salt or 

solvate thereof (as defined in Claim 2) which comprises: 
(A) for preparing a compound in which R⁴ represents nitro or C₁₋₆alkoxy, 
cyclising a compound of formula (II) 

 
in which R¹, R², R³ and R⁵ are as defined in Claim 1, R⁴ is nitro or 

C₁₋₆alkoxy and R is CN or CONH₂; 
(B) converting a compound of formula (I) to a different compound of 
formula (I); or 
(C) reacting a compound of formula (I) in which R⁴ is a reactive atom or 
group to introduce the desired R⁴ group; together, if desired or 

appropriate, with salt formation or conversion of one salt to another salt 
as an optional step subsequent to process (A), (B) or (C). 
Use of a compound of formula (I) or a physiologically acceptable salt or 
solvate thereof (as defined in Claim 1) for the manufacture of a 

medicament for the treatment of stable, unstable and variant (Prinzmetal) 
angina, hypertension, pulmonary hypertension, congestive heart failure, 

renal failure, atherosclerosis, conditions of reduced blood vessel 
patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, 

allergic asthma, allergic rhinitis, glaucoma or diseases characterised by 
disorders of gut motility. 
</CLAIMS>
</TEXT>
</DOC>
